trial · primary record
Amivantamab
Colorectal Neoplasms
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 1000 |
| Primary completion | 2032-01-20 |
| Primary endpoint | Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) |
| Registry ID | NCT06662786 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:06.745Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06662786
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Amivantamab · compound